FiercePharmaOriginal article
{"a":[{"_":"Fierce Pharma Asia—China's IIT scrutiny; Daiichi Sankyo, AZ ph. 3 win; Leo, Tanabe's dermatology deal","$":{"href":"/pharma/fierce-pharma-asia-chinas-iit-unravels-daiichi-sankyo-az-ph3-win-leo-tanabe-derm-deal","hreflang":"en"}}]}
Phase 3positiveEnhertudersimelagonPositive
AI Analysis
Summary
AstraZeneca and Daiichi Sankyo's Enhertu demonstrated positive phase 3 results in non-small cell lung cancer. Separately, Tanabe Pharma secured a $435 million deal with Leo Pharma for global rights to dermatology rare disease treatment dersimelagon.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Enhertu met endpoints in phase 3 non-small cell lung cancer trial
Importance:7/10
Sentiment:
0.70
phase 3 dataoncologypartnershipacquisitiondermatologyrare disease
Read the original article
Published by FiercePharma on August 20, 2026 2:11 PM